Corporate Profile
NovaBay is focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and community environments. Many of these infections have become increasingly difficult to treat because of the rapid increase in infectious microbes that have become resistant to current drugs. Our in vitro and in vivo tests have demonstrated that our compounds kill a wide range of bacteria, viruses and other infection-causing microbes, including those that are resistant to multiple antibiotics. We are developing hospital indications ourselves and have partnered certain other indications with Alcon, the world's leading eye care company, and with Galderma S.A., a global leading pharmaceutical company dedicated exclusively to the field of dermatology.
News and FeaturesFebruary 04, 2010
NovaBay Pharmaceuticals to Present at the 2010 BIO CEO & Investor Conference
February 2, 2010
"Towards a New Paradigm in Anti-Microbial Therapy", By Dr. Stephen Wilmarth, NovaBay Ophthalmic Advisor
January 11, 2010
NovaBay Pharmaceuticals Earns $3.75 Million in Milestone Payments from Galderma, S.A.
January 7, 2010
NovaBay Pharmaceuticals to Present at the Annual OneMedPlace Finance Forum
January 5, 2010
Founding Director of UCLA's Urological Center and NovaBay SAB Member, Bernard Churchill, M.D., Interviewed
Click Here To Listen
December 22, 2010
World-Renowned Biofilm Expert and NovaBay SAB Member, William Costerton, Ph.D., Interviewed
Click Here To Listen
December 17, 2009
NovaBay Pharmaceuticals to Receive Increase in Funding and Support from Alcon
